This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Abbott wins German approval for Exact Sciences deal

( January 30, 2026, 09:31 GMT | Official Statement) -- MLex Summary: Pharmaceutical company Abbott has secured clearance from Germany's competition authority to take over biotechnology company Exact Sciences, the Bundeskartellamt said Friday. Both companies are active in oncological molecular diagnostics, and they both distribute products in Germany that are used in breast cancer cases. Despite that, the authority said it could clear the deal without carrying out an in-depth review because the genetic tests offered by them cannot be considered as substitute products.Statement follows....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login